Last reviewed · How we verify
NCT03666962
Evaluating Medication Adherence to Novel Oral Anticoagulants With Anticoagulant Activity Monitoring in Patients With Atrial Fibrillation
trial in Anticoagulants in 200 participants. Status unknown.
31 December 2020
Quick facts
| Lead sponsor | Cui Yimin |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 September 2018 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 December 2020 |
| Sites | 7 locations across China |
Conditions studied
- Anticoagulants — all drugs for Anticoagulants →
- Compliance, Medication — all drugs for Compliance, Medication →
Sponsor
Cui Yimin
Who can join
Eligibility, any sex, with Anticoagulants or Compliance, Medication. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The novel oral anticoagulants such as rivaroxaban, apixaban and dabigatran, specifically target either thrombin or factor Xa/IIa. These new agents are included as an option for prevention of thromboembolic disease or recurrent stroke in patients with non-valvular atrial fibrillation in guidelines. Although the benefits and risks of anticoagulation and antiplatelet therapy have been fully assessed, and reasonable anticoagulation and antiplatelet therapies have been formulated, the therapeutic effect still largely depends on the quality control during the treatment. Many patients discontinue anticoagulant therapy after discharge or after a period of treatment, and the risk of thrombosis increases. Because non-vitamin K antagonist oral anticoagulants (NOACs) does not need routine monitoring, patients tend to ignore the regular medication, thus affecting drug compliance. Because of the short half-life of NOACs, if patients do not take it regularly, not only can not achieve the effectiveness of anticoagulation, but also reduce the safety of medication. More and more researchers have realized that medication adherence plays a key role in medical management. In order to improve the efficacy and safety of NOACs and the compliance of patients with NOACs, the guidelines emphasize that supplementary measures can be taken, such as pharmacists participating in the network pharmacy database, attaching importance to the medication education of patients and their families, formulating a strict follow-up plan and professional outpatient follow-up.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Anti-FXa-IIa activity test in Asian and its potential role for drug adherence evaluation in patients with direct oral anticoagulants: a nationwide multi-center synchronization study.
Liu Z, Xie Q, Xiang Q, Zhang H, et al · · 2020 · cited 5× · PMID 33224753 · DOI 10.21037/cdt-20-564
Verify or expand the search:
- PubMed search for NCT03666962
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anticoagulants
Currently open trials in the same condition.
- NCT06401863 — Shared Decision for Drug Interactions in Oral Anticoagulation · NA · recruiting
- NCT04861103 — Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH) · Phase 4 · recruiting
Other Cui Yimin trials
Trials by the same sponsor.
- NCT03670446 — Pharmacists' Intervention in Patients Using Novel Oral Anticoagulants：A Study on Behavioral Patterns · NA · unknown
- NCT03613337 — Effect of Smoking Status and Genetic Risk Factors on Restenosis and Efficacy of Clopidogrel After de Novo Percutaneous C · unknown
- NCT03779022 — miRNA and Relevant Biomarkers of BC Patients Undergoing Neoadjuvant Treatment · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03666962 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cui Yimin
- Last refreshed: 11 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03666962.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing